{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:46:41Z","timestamp":1782215201690,"version":"3.54.5"},"reference-count":178,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["R01AI140245"],"award-info":[{"award-number":["R01AI140245"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["R21AI143399"],"award-info":[{"award-number":["R21AI143399"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["75N93019C00052"],"award-info":[{"award-number":["75N93019C00052"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The emergence of novel viral infections of zoonotic origin and mutations of existing human pathogenic viruses represent a serious concern for public health. It warrants the establishment of better interventions and protective therapies to combat the virus and prevent its spread. Surface glycoproteins catalyzing the fusion of viral particles and host cells have proven to be an excellent target for antivirals as well as vaccines. This review focuses on recent advances for computational structure-based design of antivirals and vaccines targeting viral fusion machinery to control seasonal and emerging respiratory viruses.<\/jats:p>","DOI":"10.3390\/v13071320","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T10:42:17Z","timestamp":1625740937000},"page":"1320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting Viral Surface Proteins through Structure-Based Design"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4358-2912","authenticated-orcid":false,"given":"Yogesh B","family":"Narkhede","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5587-3613","authenticated-orcid":false,"given":"Karen J","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Institute of Bioinformatics, University of Georgia, Athens, GA 30602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7382-747X","authenticated-orcid":false,"given":"Eva-Maria","family":"Strauch","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA"},{"name":"Institute of Bioinformatics, University of Georgia, Athens, GA 30602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1743-422X-6-207","article-title":"From where did the 2009 \u201cswine-origin\u201d influenza A virus (H1N1) emerge?","volume":"6","author":"Gibbs","year":"2009","journal-title":"Virol. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMoa0903810","article-title":"Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans","volume":"360","author":"Jain","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Reperant, L.A., Moesker, F.M., and Osterhaus, A.D.M.E. (2016). Influenza: From zoonosis to pandemic. ERJ Open Res., 2.","DOI":"10.1183\/23120541.00013-2016"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"20180257","DOI":"10.1098\/rstb.2018.0257","article-title":"A brief history of bird flu","volume":"374","author":"Lycett","year":"2019","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/S0140-6736(13)60938-1","article-title":"Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: Phylogenetic, structural, and coalescent analyses","volume":"381","author":"Liu","year":"2013","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(04)15595-5","article-title":"Re-emergence of fatal human influenza A subtype H5N1 disease","volume":"363","author":"Peiris","year":"2004","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Paget, J., Spreeuwenberg, P., Charu, V., Taylor, R.J., Iuliano, A.D., Bresee, J., Simonsen, L., and Viboud, C. (2019). Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J. Glob. Health, 9.","DOI":"10.7189\/jogh.09.020421"},{"key":"ref_11","unstructured":"(2021, March 22). COVID-19 Map\u2014Johns Hopkins Coronavirus Resource Center. Available online: https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hu, B., Zeng, L.-P., Yang, X.-L., Ge, X.-Y., Zhang, W., Li, B., Xie, J.-Z., Shen, X.-R., Zhang, Y.-Z., and Wang, N. (2017). Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLOS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006698"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1126\/science.1118391","article-title":"Bats are natural reservoirs of SARS-like coronaviruses","volume":"310","author":"Li","year":"2005","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.1087139","article-title":"Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China","volume":"302","author":"Guan","year":"2003","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-020-2169-0","article-title":"Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins","volume":"583","author":"Lam","year":"2020","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41467-021-21240-1","article-title":"Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia","volume":"12","author":"Wacharapluesadee","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3201\/eid2602.190697","article-title":"Middle east respiratory syndrome coronavirus transmission","volume":"26","author":"Killerby","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/zph.12435","article-title":"Zoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE","volume":"65","author":"Paden","year":"2018","journal-title":"Zoonoses Public Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tvjl.2016.12.020","article-title":"Middle East respiratory syndrome (MERS) coronavirus and dromedaries","volume":"220","author":"Wernery","year":"2017","journal-title":"Vet. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.1213362","article-title":"Airborne transmission of influenza A\/H5N1 virus between ferrets","volume":"336","author":"Herfst","year":"2012","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature10831","article-title":"Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA\/H1N1 virus in ferrets","volume":"486","author":"Imai","year":"2012","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1126\/science.abc0523","article-title":"Cryptic transmission of SARS-CoV-2 in Washington state","volume":"370","author":"Bedford","year":"2020","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","article-title":"Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.chom.2021.02.003","article-title":"Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_26","unstructured":"(2021, May 11). Understanding mRNA COVID-19 Vaccines | CDC, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/mrna.html."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100766","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","article-title":"The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine\u2014United States, December 2020","volume":"69","author":"Oliver","year":"2020","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","article-title":"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers\u2014Eight U.S. Locations, December 2020\u2013March","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"ref_35","first-page":"1","article-title":"Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis","volume":"8","author":"Kirchdoerfer","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV - A target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbrc.2004.10.052","article-title":"Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry","volume":"325","author":"He","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1016\/j.vaccine.2015.08.056","article-title":"Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats","volume":"33","author":"Widjojoatmodjo","year":"2015","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"12265","DOI":"10.1073\/pnas.1811980115","article-title":"Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1\u20134","volume":"115","author":"Chuang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.virol.2015.03.043","article-title":"Viral membrane fusion","volume":"479\u2013480","author":"Harrison","year":"2015","journal-title":"Virology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nsmb.1456","article-title":"Viral membrane fusion","volume":"15","author":"Harrison","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrmicro1326","article-title":"Virus membrane-fusion proteins: More than one way to make a hairpin","volume":"4","author":"Kielian","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Albertini, A., Bressanelli, S., Lepault, J., and Gaudin, Y. (2011). Structure and Working of Viral Fusion Machinery, Academic Press Inc.","DOI":"10.1016\/B978-0-12-385891-7.00003-9"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/09687860400017784","article-title":"Class I and class II viral fusion protein structures reveal similar principles in membrane fusion","volume":"21","author":"Schibli","year":"2004","journal-title":"Mol. Membr. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/371037a0","article-title":"Structure of influenza haemagglutinin at the pH of membrane fusion","volume":"371","author":"Bullough","year":"1994","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.virol.2005.09.036","article-title":"Class II virus membrane fusion proteins","volume":"344","author":"Kielian","year":"2006","journal-title":"Virology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-cellbio-101512-122422","article-title":"Virus and Cell Fusion Mechanisms","volume":"30","author":"Podbilewicz","year":"2014","journal-title":"Annu. Rev. Cell Dev. Biol"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10409230802058320","article-title":"Structures and mechanisms of viral membrane fusion proteins: Multiple variations on a common theme","volume":"43","author":"White","year":"2008","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_53","unstructured":"Gaudin, Y. (2000). Reversibility in Fusion Protein Conformational Changes The Intriguing Case of Rhabdovirus-Induced Membrane Fusion. Fusion of Biological Membranes and Related Problems, Kluwer Academic Publishers."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.sbi.2009.02.012","article-title":"Class III viral membrane fusion proteins","volume":"19","author":"Backovic","year":"2009","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Izaguirre, G. (2019). The Proteolytic Regulation of Virus Cell Entry by Furin and Other Proprotein Convertases. Viruses, 11.","DOI":"10.3390\/v11090837"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1073\/pnas.0809524106","article-title":"Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites","volume":"106","author":"Belouzard","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/387426a0","article-title":"Atomic structure of the ectodomain from HIV-1 gp41","volume":"387","author":"Weissenhorn","year":"1997","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1073\/pnas.79.4.968","article-title":"Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus mediated membrane fusion","volume":"79","author":"Skehel","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/0042-6822(86)90210-2","article-title":"Conformational changes in the hemagglutinin of influenza virus which accompany heat-induced fusion of virus with liposomes","volume":"155","author":"Ruigrok","year":"1986","journal-title":"Virology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"12205","DOI":"10.1073\/pnas.92.26.12205","article-title":"A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation","volume":"92","author":"Chen","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0092-8674(00)81771-7","article-title":"Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation","volume":"95","author":"Chen","year":"1998","journal-title":"Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, Function, and Evolution of Coronavirus Spike Proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrmicro2147","article-title":"Coronaviruses post-SARS: Update on replication and pathogenesis","volume":"7","author":"Perlman","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.biochem.70.1.777","article-title":"Mechanisms of viral membrane fusion and its inhibition","volume":"70","author":"Eckert","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"Matthews","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1128\/JVI.73.7.6089-6092.1999","article-title":"Role of the Membrane-Proximal Domain in the Initial Stages of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Membrane Fusion","volume":"73","author":"Salzwedel","year":"1999","journal-title":"J. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/aid.1993.9.1051","article-title":"A Synthetic Peptide from HIV-1 gp41 is a Potent Inhibitor of Virus-Mediated Cell\u2014Cell Fusion","volume":"9","author":"Wild","year":"1993","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1093\/emboj\/cdf559","article-title":"Reversible stages of the low-pH-triggered conformational change in influenza virus hemagglutinin","volume":"21","author":"Leikina","year":"2002","journal-title":"EMBO J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.febslet.2007.01.093","article-title":"Virus membrane fusion","volume":"581","author":"Weissenhorn","year":"2007","journal-title":"FEBS Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nature11414","article-title":"Cross-neutralization of influenza A viruses mediated by a single antibody loop","volume":"489","author":"Ekiert","year":"2012","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"17040","DOI":"10.1073\/pnas.1212371109","article-title":"Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity","volume":"109","author":"Lee","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","first-page":"1","article-title":"Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus","volume":"5","author":"Lee","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.2105\/AJPH.2018.304609","article-title":"Timely antiviral administration during an influenza pandemic: Key components","volume":"108","author":"Koonin","year":"2018","journal-title":"Am. J. Public Health"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.280.10.887","article-title":"Oral famciclovir for the suppression of recurrent genital herpes: A randomized controlled trial","volume":"280","author":"Sibbald","year":"1998","journal-title":"J. Am. Med. Assoc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/hep.20110","article-title":"Chronic hepatitis B: Update of recommendations","volume":"39","author":"Lok","year":"2004","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Olchanski, N., Hansen, R.N., Pope, E., D\u2019Cruz, B., Fergie, J., Goldstein, M., Krilov, L.R., McLaurin, K.K., Nabrit-Stephens, B., and Oster, G. (2018). Palivizumab prophylaxis for respiratory syncytial virus: Examining the evidence around value. Open Forum Infect. Dis., 5.","DOI":"10.1093\/ofid\/ofy031"},{"key":"ref_78","first-page":"1","article-title":"A meta-analysis of the efficacy of HAART on HIV transmission and its impact on sexual risk behaviours among men who have sex with men","volume":"10","author":"Jiang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM199604183341602","article-title":"Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine","volume":"334","author":"Collier","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.chom.2020.09.017","article-title":"Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics","volume":"28","author":"Grobler","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMp2032369","article-title":"FDA Approval of Remdesivir\u2014A Step in the Right Direction","volume":"383","author":"Rubin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_82","unstructured":"(2021, March 29). FDA Approves First Treatment for COVID-19 | FDA, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40506-016-0085-5","article-title":"Japanese Surveillance Systems and Treatment for Influenza","volume":"8","author":"Zaraket","year":"2016","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_88","unstructured":"(2021, March 29). New Data Show Treatment with Lilly\u2019s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced risk of COVID-19 Hospitalizations and Death by 70 Percent | Eli Lilly and Company. Available online: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/new-data-show-treatment-lillys-neutralizing-antibodies."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0014-5793(91)80804-C","article-title":"The cystatins: Protein inhibitors of cysteine proteinases","volume":"285","author":"Turk","year":"1991","journal-title":"FEBS Lett."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1202617","article-title":"Computational design of proteins targeting the conserved stem region of influenza hemagglutinin","volume":"332","author":"Fleishman","year":"2011","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nature23912","article-title":"Massively parallel de novo protein design for targeted therapeutics","volume":"550","author":"Chevalier","year":"2017","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1204839","article-title":"A highly conserved neutralizing epitope on group 2 influenza A viruses","volume":"333","author":"Ekiert","year":"2011","journal-title":"Science"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nbt.3907","article-title":"Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site","volume":"35","author":"Strauch","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.abd9909","article-title":"De novo design of picomolar SARS-CoV-2 miniprotein inhibitors","volume":"370","author":"Cao","year":"2020","journal-title":"Science"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Bricker, T.L., Darling, T.L., Hassan, A.O., Harastani, H.H., Soung, A., Jiang, X., Dai, Y.N., Zhao, H., Adams, L.J., and Holtzman, M.J. (2020). A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. bioRxiv.","DOI":"10.1101\/2020.12.02.408823"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"9499","DOI":"10.1128\/JVI.01373-15","article-title":"Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate","volume":"89","author":"Liang","year":"2015","journal-title":"J. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.tim.2017.09.009","article-title":"Clinical Potential of Prefusion RSV F-specific Antibodies","volume":"26","author":"Rossey","year":"2018","journal-title":"Trends Microbiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix503","article-title":"An Adjuvanted, Postfusion F Protein\u2013Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults","volume":"216","author":"Falloon","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.coviro.2017.03.012","article-title":"Vaccine development for respiratory syncytial virus","volume":"23","author":"Graham","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12967-015-0705-8","article-title":"Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein","volume":"13","author":"Cullen","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Griffin, M.P., Khan, A.A., Esser, M.T., Jensen, K., Takas, T., Kankam, M.K., Villafana, T., and Dubovsky, F. (2017). Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01714-16"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01708-9","article-title":"Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein","volume":"8","author":"Battles","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20321-x","article-title":"Stabilizing the closed SARS-CoV-2 spike trimer","volume":"12","author":"Juraszek","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 Spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8119","DOI":"10.1016\/j.vaccine.2018.10.032","article-title":"Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability","volume":"36","author":"Zhang","year":"2018","journal-title":"Vaccine"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature17200","article-title":"Pre-fusion structure of a human coronavirus spike protein","volume":"531","author":"Kirchdoerfer","year":"2016","journal-title":"Nature"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nsmb.3267","article-title":"Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV","volume":"23","author":"Joyce","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Stewart-Jones, G.B.E., Thomas, P.V., Chen, M., Druz, A., Joyce, M.G., Kong, W.P., Sastry, M., Soto, C., Yang, Y., and Zhang, B. (2015). A cysteine zipper stabilizes a pre-fusion F glycoprotein vaccine for respiratory syncytial virus. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128779"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature12966","article-title":"Proof of principle for epitope-focused vaccine design","volume":"507","author":"Correia","year":"2014","journal-title":"Nature"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.str.2010.06.010","article-title":"Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope","volume":"18","author":"Correia","year":"2010","journal-title":"Structure"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"17880","DOI":"10.1073\/pnas.1004728107","article-title":"Elicitation of structure-specific antibodies by epitope scaffolds","volume":"107","author":"Ofek","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jmb.2011.04.044","article-title":"Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus","volume":"409","author":"McLellan","year":"2011","journal-title":"J. Mol. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1209368","article-title":"Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold","volume":"334","author":"Azoitei","year":"2011","journal-title":"Science"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jmb.2011.10.003","article-title":"Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope","volume":"415","author":"Azoitei","year":"2012","journal-title":"J. Mol. Biol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","article-title":"Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract","volume":"368","author":"Wu","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nsmb.1723","article-title":"Structural basis of respiratory syncytial virus neutralization by motavizumab","volume":"17","author":"McLellan","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Sesterhenn, F., Yang, C., Bonet, J., Cramer, J.T., Wen, X., Wang, Y., Chiang, C.I., Abriata, L.A., Kucharska, I., and Castoro, G. (2020). De novo protein design enables the precise induction of RSV-neutralizing antibodies. Science, 368.","DOI":"10.1126\/science.aay5051"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"12236","DOI":"10.1128\/JVI.01579-10","article-title":"Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F","volume":"84","author":"McLellan","year":"2010","journal-title":"J. Virol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nature04817","article-title":"Distribution and three-dimensional structure of AIDS virus envelope spikes","volume":"441","author":"Zhu","year":"2006","journal-title":"Nature"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Vahey, M.D., and Fletcher, D.A. (2019). Influenza A virus surface proteins are organized to help penetrate host mucus. Elife, 8.","DOI":"10.7554\/eLife.43764"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0076-6879(04)83004-0","article-title":"Protein Structure Prediction Using Rosetta","volume":"383","author":"Rohl","year":"2004","journal-title":"Methods Enzymol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature13404","article-title":"Accurate design of co-assembling multi-component protein nanomaterials","volume":"510","author":"King","year":"2014","journal-title":"Nature"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1126\/science.aaf8818","article-title":"Accurate design of megadalton-scale two-component icosahedral protein complexes","volume":"353","author":"Bale","year":"2016","journal-title":"Science"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.57659","article-title":"Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens","volume":"9","author":"Ueda","year":"2020","journal-title":"Elife"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Boyoglu-Barnum, S., Ellis, D., Gillespie, R.A., Hutchinson, G.B., Park, Y.-J., Moin, S.M., Acton, O.J., Ravichandran, R., Murphy, M., and Pettie, D. (2021). Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature, 1\u20136.","DOI":"10.1038\/s41586-021-03365-x"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00430-002-0132-3","article-title":"Antigenic drift and variability of influenza viruses","volume":"191","author":"Schweiger","year":"2002","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","article-title":"Next-generation influenza vaccines: Opportunities and challenges","volume":"19","author":"Wei","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_134","first-page":"43","article-title":"Seasonal influenza vaccines","volume":"333","author":"Fiore","year":"2009","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"McMillan, C.L.D., Young, P.R., Watterson, D., and Chappell, K.J. (2021). The next generation of influenza vaccines: Towards a universal solution. Vaccines, 9.","DOI":"10.3390\/vaccines9010026"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/289366a0","article-title":"Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 \u00c5 resolution","volume":"289","author":"Wilson","year":"1981","journal-title":"Nature"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-017-0918-y","article-title":"Towards a universal influenza vaccine: Different approaches for one goal","volume":"15","author":"Sautto","year":"2018","journal-title":"Virol. J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.imbio.2017.10.040","article-title":"Human monoclonal antibodies neutralizing influenza virus A\/H1N1pdm09 and seasonal A\/H1N1 strains\u2014Distinct Ig gene repertoires with a similar action mechanism","volume":"223","author":"Hiroi","year":"2018","journal-title":"Immunobiology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.vaccine.2011.01.100","article-title":"A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets","volume":"29","author":"Giles","year":"2011","journal-title":"Vaccine"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1128\/JVI.03152-15","article-title":"Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses","volume":"90","author":"Carter","year":"2016","journal-title":"J. Virol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/JVI.01581-17","article-title":"Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants","volume":"91","author":"Wong","year":"2017","journal-title":"J. Virol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"W214","DOI":"10.1093\/nar\/gki385","article-title":"GlyProt: In silico glycosylation of proteins","volume":"33","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"ref_143","unstructured":"Schr\u00f6dinger, L. (2015). The PyMOL Molecular Graphics System, Schr\u00f6dinger LLC. Version 1.8."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.1128\/JVI.01388-13","article-title":"Antibody Recognition of the Pandemic H1N1 Influenza Virus Hemagglutinin Receptor Binding Site","volume":"87","author":"Hong","year":"2013","journal-title":"J. Virol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.coviro.2013.07.007","article-title":"Influenza virus hemagglutinin stalk-based antibodies and vaccines","volume":"3","author":"Krammer","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Throsby, M., van den Brink, E., Jongeneelen, M., Poon, L.L.M., Alard, P., Cornelissen, L., Bakker, A., Cox, F., van Deventer, E., and Guan, Y. (2008). Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003942"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","article-title":"Antibody recognition of a highly conserved influenza virus epitope","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses","volume":"16","author":"Sui","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"13133","DOI":"10.1073\/pnas.1414070111","article-title":"Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans","volume":"111","author":"Ellebedy","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1128\/JVI.01336-12","article-title":"Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice","volume":"86","author":"Krammer","year":"2012","journal-title":"J. Virol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/infdis\/jis652","article-title":"1976 and 2009 H1N1 Influenza Virus Vaccines Boost Anti-Hemagglutinin Stalk Antibodies in Humans","volume":"207","author":"Miller","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/cid\/cir121","article-title":"Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza a antibodies","volume":"52","author":"Sui","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coi.2016.05.012","article-title":"Heads, stalks and everything else: How can antibodies eradicate influenza as a human disease?","volume":"42","author":"Neu","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_155","first-page":"1","article-title":"A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice","volume":"1","author":"Nachbagauer","year":"2016","journal-title":"Jpn. Vaccines"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Ermler, M.E., Kirkpatrick, E., Sun, W., Hai, R., Amanat, F., Chromikova, V., Palese, P., and Krammer, F. (2017). Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model. J. Virol., 91.","DOI":"10.1128\/JVI.00286-17"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1128\/JVI.00641-13","article-title":"Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies","volume":"87","author":"Krammer","year":"2013","journal-title":"J. Virol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1128\/JVI.00137-12","article-title":"Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes","volume":"86","author":"Hai","year":"2012","journal-title":"J. Virol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","article-title":"A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial","volume":"27","author":"Nachbagauer","year":"2021","journal-title":"Nat. Med."},{"key":"ref_160","first-page":"1","article-title":"A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains","volume":"4","author":"Broecker","year":"2019","journal-title":"Jpn. Vaccines"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Sun, W., Kirkpatrick, E., Ermler, M., Nachbagauer, R., Broecker, F., Krammer, F., and Palese, P. (2019). Development of Influenza B Universal Vaccine Candidates Using the \u201cMosaic\u201d Hemagglutinin Approach. J. Virol., 93.","DOI":"10.1128\/JVI.00333-19"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/infdis\/jiy711","article-title":"Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain","volume":"219","author":"Krammer","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep22666","article-title":"Stalking influenza by vaccination with pre-fusion headless HA mini-stem","volume":"6","author":"Valkenburg","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1073\/pnas.1308701110","article-title":"Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines","volume":"111","author":"Lu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Corbett, K.S., Moin, S.M., Yassine, H.M., Cagigi, A., Kanekiyo, M., Boyoglu-Barnum, S., Myers, S.I., Tsybovsky, Y., Wheatley, A.K., and Schramm, C.A. (2019). Design of nanoparticulate group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages. MBio, 10.","DOI":"10.1128\/mBio.02810-18"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Steel, J., Lowen, A.C., Wang, T.T., Yondola, M., Gao, Q., Haye, K., Garc\u00eda-Sastre, A., and Palesea, P. (2010). Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio, 1.","DOI":"10.1128\/mBio.00018-10"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"13434","DOI":"10.1128\/JVI.01429-12","article-title":"Design of Escherichia coli-Expressed Stalk Domain Immunogens of H1N1 Hemagglutinin That Protect Mice from Lethal Challenge","volume":"86","author":"Bommakanti","year":"2012","journal-title":"J. Virol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"E2514","DOI":"10.1073\/pnas.1402766111","article-title":"Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection","volume":"111","author":"Mallajosyula","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fimmu.2015.00329","article-title":"Hemagglutinin sequence conservation guided stem immunogen design from influenza A H3 subtype","volume":"6","author":"Mallajosyula","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1016\/j.vaccine.2015.05.038","article-title":"Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses","volume":"33","author":"Wohlbold","year":"2015","journal-title":"Vaccine"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.virol.2018.10.005","article-title":"Development of a universal influenza vaccine using hemagglutinin stem protein produced from Pichia pastoris","volume":"526","author":"Wang","year":"2019","journal-title":"Virology"},{"key":"ref_173","unstructured":"(2021, June 06). National Institute of Allergy and Infectious Diseases (NIAID) Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03186781."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Lin, S.-C., Lin, Y.-F., Chong, P., and Wu, S.-C. (2012). Broader Neutralizing Antibodies against H5N1 Viruses Using Prime-Boost Immunization of Hyperglycosylated Hemagglutinin DNA and Virus-Like Particles. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039075"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Lin, S.-C., Liu, W.-C., Jan, J.-T., and Wu, S.-C. (2014). Glycan Masking of Hemagglutinin for Adenovirus Vector and Recombinant Protein Immunizations Elicits Broadly Neutralizing Antibodies against H5N1 Avian Influenza Viruses. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092822"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.chom.2019.04.003","article-title":"Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope","volume":"25","author":"Bajic","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1128\/JVI.02608-13","article-title":"Guiding the Immune Response against Influenza Virus Hemagglutinin toward the Conserved Stalk Domain by Hyperglycosylation of the Globular Head Domain","volume":"88","author":"Eggink","year":"2014","journal-title":"J. Virol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"8496","DOI":"10.1128\/JVI.00880-16","article-title":"Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design","volume":"90","author":"Liu","year":"2016","journal-title":"J. Virol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:27:51Z","timestamp":1760164071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":178,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["v13071320"],"URL":"https:\/\/doi.org\/10.3390\/v13071320","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]}}}